Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.US-based drug maker Pfizer is planning to submit a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for palbociclib, combined with letrozole, as first-line systemic treatment of post-menopausal women with estrogen receptor positive (ER+), human epidermal growth factor receptor 2 negative (HER2-) locally advanced or metastatic breast cancer.
Subscribe to our email newsletter
The submission is expected to take place in the third quarter of 2014 based on discussions with the FDA regarding the final results of PALOMA-1, a randomized, Phase II trial comparing palbociclib plus letrozole versus letrozole alone in these patients.
In April 2013, the investigational oral targeted agent palbociclib received FDA Breakthrough Therapy designation for the first-line systemic treatment of women with advanced or metastatic ER+, HER2- breast cancer.
The FDA breakthrough therapy status was based on interim data from the PALOMA-1 trial.
The company said that palbociclib selectively inhibits cyclin-dependent kinases (CDKs) 4 and 6 to regain cell cycle control and block tumor cell proliferation.
Loss of cell cycle control is a hallmark of cancer and CDK 4/6 are overactivated in several cancers, leading to loss of proliferative control.
The trial is designed to evaluate progression-free survival in post-menopausal women with ER+, HER2- advanced breast cancer receiving palbociclib (125mg once daily for three out of four weeks in repeated cycles) in combination with letrozole versus letrozole alone (2.5mg once daily on a continuous regimen).
The PALOMA-1 trial is carried out in collaboration with the Jonsson Cancer Center’s Revlon/UCLA Women’s Cancer Research Program, led by Dr. Dennis Slamon.